Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,441 stopped studies mapped to Leukemia and descendants · 87% state a reason
Over the 1,441 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00651716 | T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem… | — | terminated | Apr 3, 2008 | Vanderbilt-Ingram Cancer Center | Funding unavailable | Funding |
| NCT01754870 | Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by… | Phase 2 | withdrawn | Dec 21, 2012 | University of Wisconsin, Madison | slow accrual | Enrollment / accrual |
| NCT02343939 | Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute…(ENTO in AML) | Phase 1 / Phase 2 | terminated | Jan 22, 2015 | Gilead Sciences | not stated | Not stated |
| NCT03126864 | Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to… | Phase 1 | terminated | Apr 24, 2017 | M.D. Anderson Cancer Center | Terminated per the PI's request. | Other (stated, no rule matched) |
| NCT03612739 | EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2(EPITHINK) | Phase 1 | withdrawn | Aug 2, 2018 | Celyad Oncology SA | Sponsor decision | Sponsor / business decision |
| NCT03195010 | Management of Platelet Transfusion Therapy in Patients With Blood Cancer or… | Phase 2 | terminated | Jun 22, 2017 | Fred Hutchinson Cancer Center | Terminated because of slow recruitment and lack of funding support | Enrollment / accrual |
| NCT01747499 | Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation | Phase 1 / Phase 2 | terminated | Dec 11, 2012 | Washington University School of Medicine | Enrolling 8 more patients would be statistically unlikely that the primary endpoint would be… | Enrollment / accrual |
| NCT00568633 | Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML | Phase 3 | terminated | Dec 6, 2007 | Stanford University | Poor accrual | Enrollment / accrual |
| NCT01873495 | Omacetaxine for Consolidation and Maintenance | Phase 2 | terminated | Jun 10, 2013 | Emory University | not stated | Not stated |
| NCT02399917 | Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid… | Phase 2 | terminated | Mar 26, 2015 | M.D. Anderson Cancer Center | This study was terminated early due to response rates not meeting the anticipated minimum of 30%. | Other (stated, no rule matched) |
| NCT02784834 | Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL | Phase 1 | terminated | May 27, 2016 | Michael Choi | lack of funding | Funding |
| NCT01289678 | Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia | Phase 2 | terminated | Feb 4, 2011 | Leo W. Jenkins Cancer Center | Unable to meet accrual goals | Enrollment / accrual |
| NCT01253460 | Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia,… | Phase 2 | terminated | Dec 3, 2010 | M.D. Anderson Cancer Center | Accrual not met | Enrollment / accrual |
| NCT01408160 | Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory… | Phase 1 | terminated | Aug 3, 2011 | Albert Einstein College of Medicine | not stated | Not stated |
| NCT03672851 | Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With… | Phase 1 | terminated | Sep 17, 2018 | Second Affiliated Hospital of Xi'an Jiaotong University | adverse effect | Safety / toxicity |
| NCT00276159 | Study of Immune Response Modifier in the Treatment of Hematologic Malignancies | Phase 2 | terminated | Jan 13, 2006 | Masonic Cancer Center, University of Minnesota | Drug was not available. | Other (stated, no rule matched) |
| NCT02614508 | Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory… | Phase 1 | terminated | Nov 25, 2015 | Emory University | not stated | Not stated |
| NCT02053545 | Haplo-identical SCT for High Risk (HR) Hematologic Malignancies w/Post-Transplant In-Vivo… | Phase 1 / Phase 2 | withdrawn | Feb 3, 2014 | Ann & Robert H Lurie Children's Hospital of Chicago | Study closed with no enrollment. | Enrollment / accrual |
| NCT01090414 | An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101;… | Phase 1 / Phase 2 | terminated | Mar 22, 2010 | Gilead Sciences | not stated | Not stated |
| NCT01160354 | Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute… | Phase 1 / Phase 2 | terminated | Jul 12, 2010 | M.D. Anderson Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT03395873 | Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are… | Phase 1 | terminated | Jan 10, 2018 | Milton S. Hershey Medical Center | Recent FDA approval of a new drug for the same patient population | Other (stated, no rule matched) |
| NCT01539291 | Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who… | Phase 3 | terminated | Feb 27, 2012 | Gilead Sciences | not stated | Not stated |
| NCT00949988 | A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia(BMS-CA180105) | Phase 1 / Phase 2 | terminated | Jul 31, 2009 | University of California, San Diego | Three subjects were enrolled and all three subjects withdrew. | Enrollment / accrual |
| NCT01659021 | Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated… | Phase 3 | terminated | Aug 7, 2012 | Gilead Sciences | not stated | Not stated |
| NCT02337478 | Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute… | Phase 2 | terminated | Jan 13, 2015 | Wake Forest University Health Sciences | The study was stopped early due to futility. | Efficacy / futility |
| NCT02535806 | Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children… | Phase 2 | terminated | Aug 31, 2015 | Children's Mercy Hospital Kansas City | Funding source discontinued | Funding |
| NCT03547154 | Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^®… | Phase 2 / Phase 3 | terminated | Jun 6, 2018 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT02634827 | Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid… | Phase 2 | terminated | Dec 18, 2015 | Mayo Clinic | not stated | Not stated |
| NCT00167180 | Post Transplant Donor Lymphocyte Infusion | Phase 2 | terminated | Sep 14, 2005 | Masonic Cancer Center, University of Minnesota | Accrual Goal Met | Enrollment / accrual |
| NCT01039376 | Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to…(PROLONG) | Phase 3 | terminated | Dec 25, 2009 | Novartis Pharmaceuticals | Sponsor decision | Sponsor / business decision |
| NCT00882076 | Clofarabine, Etoposide, and Mitoxantrone for Relapsed and Refractory Acute Leukemias | Phase 1 | terminated | Apr 16, 2009 | Milton S. Hershey Medical Center | study closed prematurely | Other (stated, no rule matched) |
| NCT02360111 | GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal… | N/A | terminated | Feb 10, 2015 | Memorial Sloan Kettering Cancer Center | Lack of accrual | Enrollment / accrual |
| NCT01875237 | Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene | Phase 1 / Phase 2 | terminated | Jun 11, 2013 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT02421926 | Extension Study of IDEAL (Imatinib) for Chronic Myelgenous Leukemia (CML)(IDEAL-E) | — | withdrawn | Apr 21, 2015 | Asan Medical Center | not stated | Not stated |
| NCT02477787 | Randomized Study of Haploidentical Hct and Subsequent Donor nk Cell Infusion in High-risk…(DNKI-4) | Phase 2 | terminated | Jun 23, 2015 | Asan Medical Center | upon recommendation from the Data Monitoring Committee | Other (stated, no rule matched) |
| NCT02177812 | A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia… | Phase 1 | terminated | Jun 30, 2014 | GlaxoSmithKline | The risk benefit in relapsed refractory AML does not favor continuation of the study. | Other (stated, no rule matched) |
| NCT00748189 | Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients…(COMPLEMENT 1) | Phase 3 | terminated | Sep 8, 2008 | Novartis Pharmaceuticals | Majority of patients (62%) had been treated with next line therapies, including new highly… | Other (stated, no rule matched) |
| NCT02848911 | Safety Study to Assess AFM11 in Patients With Relapsed or Refractory Adult B-precursor ALL | Phase 1 | terminated | Jul 29, 2016 | Affimed GmbH | Strategic decision was made to terminate the AFM11 development | Sponsor / business decision |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and… | Phase 2 | terminated | Jul 9, 2010 | City of Hope Medical Center | Low enrollment | Enrollment / accrual |
| NCT01853228 | A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children… | Phase 1 / Phase 2 | terminated | May 14, 2013 | Janssen Research & Development, LLC | EMA/PDCO acknowledged that available results from this study do not support further clinical… | Other (stated, no rule matched) |
| NCT01408043 | Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating… | N/A | terminated | Aug 3, 2011 | Case Comprehensive Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT03735446 | Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a… | Phase 1 | terminated | Nov 8, 2018 | Dana-Farber Cancer Institute | Sponsor Decision | Sponsor / business decision |
| NCT01214655 | A Study for Patients With Acute Leukemia | Phase 1 | terminated | Oct 5, 2010 | Eli Lilly and Company | Primary objective has been met in the absence of clinically meaningful remissions | Other (stated, no rule matched) |
| NCT03752138 | TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid… | Phase 1 | withdrawn | Nov 23, 2018 | M.D. Anderson Cancer Center | The supporting pharamceutical company elected not to pursue this study at this time. | Sponsor / business decision |
| NCT03373305 | Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory… | Phase 1 | withdrawn | Dec 14, 2017 | City of Hope Medical Center | contract not executed | Other (stated, no rule matched) |
| NCT02749708 | Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk… | Phase 1 | terminated | Apr 25, 2016 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Study drug supply expired and could not be renewed. | Drug supply |
| NCT03291353 | Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute… | Early Phase 1 | withdrawn | Sep 25, 2017 | Michael Boyiadzis | This study has closed due to slow accrual. | Enrollment / accrual |
| NCT02993536 | Clonal Evolution of B Cells in High-risk CLL After Idelalisib-rituximab | — | withdrawn | Dec 15, 2016 | Abramson Cancer Center at Penn Medicine | Low likelihood to usedrug in clinic practice based on emergining AE profile and data from front… | Other (stated, no rule matched) |
| NCT01974479 | Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage… | Phase 1 | suspended | Nov 1, 2013 | National University Health System, Singapore | Suspended for an interim review of (CAR) CD19 research strategy for the treatment of CD19 positive… | Sponsor / business decision |
| NCT00829647 | A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | withdrawn | Jan 27, 2009 | Scripps Health | Unable to enroll | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Nov 15, 2019source: clinicaltrials